U.S. Stock News

Northwest Natural Holding (NWN) stock is in focus after the company reported second quarter 2026 results, swung to a small net profit, and guided full year earnings per share toward the upper half of its 2026 range. See our latest analysis for Northwest Natural Holding. Northwest Natural Holding shares have edged higher in recent months, with a 90 day share price return of 2.2% and a year to date share price return of 9.16%. The 1 year total shareholder return of 30.75% and 3 year total...

Datadog (DDOG) is drawing fresh attention after securing FedRAMP High certification for Datadog for Government and partnering with Vertosoft, a move that points directly to the US public sector opportunity. See our latest analysis for Datadog. Set against these government wins, Datadog’s share price has had a mixed few weeks, with a 30 day share price return down 4.9%, a 90 day share price return of 15.9%, and a 1 year total shareholder return of 90.7%. This points to momentum that has built...

Relay Therapeutics has delivered a very large 1 year return, yet the stock currently screens as expensive on broad valuation checks, which raises questions about how much optimism is already in the price. Relay Therapeutics has returned roughly 7x over the past 12 months, which puts unusual weight on whether the fundamentals can justify that kind of move. Expectations for future drug development and potential revenue can support the current valuation, while uncertainty around clinical...

PTC Therapeutics recently held a special call to discuss the past regulatory progress of ST-920, whose Biologics License Application is supported by 52-week Phase 1/2 STAAR data showing meaningful renal benefit alongside a favorable safety and tolerability profile. This focus on ST-920’s clinical and regulatory trajectory highlights PTC’s deepening commitment to rare disease gene therapies and potential portfolio diversification beyond its current commercial base. We’ll now examine how...

Curtiss-Wright (CW) extended its share repurchase activity on August 10, 2026, adding US$100 million to its buyback authorization and bringing the total program size to US$2.166 billion. See our latest analysis for Curtiss-Wright. Curtiss-Wright’s latest buyback expansion comes after a brief period of share price softness, with the stock down over the past quarter but still showing strong year to date share price returns and very strong multi year total shareholder returns. If this kind of...

Kinder Morgan stock has delivered strong returns over the past few years, yet the current price near US$32.87 is still below an intrinsic value estimate from a Discounted Cash Flow (DCF) approach that points to roughly 40.4% upside. At the same time, market multiples suggest Kinder Morgan is trading at about the right level overall, which creates a mixed read on how much value is really left in the share price today. Over the past 5 years Kinder Morgan has returned about 161.3%, which puts...

Block stock is caught between two different valuation signals. The Excess Returns intrinsic value estimate points to meaningful upside from the current US$79.43 share price, while earnings based multiples flag the stock as expensive compared with its fundamentals. Block has declined 70.6% over the past 5 years, which leaves long term holders with a weak result and makes today’s entry point more sensitive to valuation. Recent AI driven restructuring and product rollout can support margin and...

In early August 2026, Berkshire Hathaway reported Q2 results showing revenue of US$101.81 billion and net income of US$25.67 billion, both higher than a year earlier, while also ramping up equity purchases and buybacks under new CEO Greg Abel. A key shift was Berkshire’s very large expansion of its Alphabet stake via a US$10 billion private placement and market purchases, ending a 14‑quarter stretch of net stock selling and signaling a different capital deployment approach. We’ll now examine...

Event recap and why Harrow stock is in focus Harrow (HROW) is back on investor radar after the company reiterated its 2026 revenue guidance of US$350 million to US$365 million and reported second quarter results that paired higher sales with a wider net loss. The stock has risen over the past 3 months but is down over the past month. That backdrop makes the latest guidance and earnings release an important checkpoint for anyone tracking Harrow’s eyecare focused plans. See our latest analysis...

In early August 2026, STERIS plc reported first-quarter fiscal 2027 results showing higher sales of US$1,492.7 million and increased earnings, reiterated its full-year revenue growth guidance of 7% to 8%, appointed Pierre Boulud to key board committees, and announced a US$600 million chemistries Center of Excellence in North Carolina. The combination of earnings growth, reaffirmed guidance, and the largest manufacturing investment in the company’s history highlights management’s confidence...

The United States market remained flat over the last week but has seen a 20% increase over the past year, with earnings forecasted to grow by 17% annually. In this environment, identifying undervalued stocks like OceanFirst Financial can provide opportunities for investors seeking value in companies priced below their estimated worth.

In the last week, the United States market has remained flat, although it is up 20% over the past year with earnings forecasted to grow by 17% annually. In such a promising environment, growth companies with high insider ownership can be particularly appealing as insiders' confidence in their own firms often signals potential for sustained expansion and value creation.

Over the last 7 days, the United States market has remained flat, although it is up 20% over the past year, with earnings expected to grow by 17% per annum in the coming years. The term 'penny stocks' might feel like a relic of past market eras, but they continue to represent real potential for investors seeking affordability and growth when backed by strong financials. In this article, we will explore several penny stocks that stand out for their financial strength and potential for...

Brown-Forman stock has delivered a steep decline of about 56.6% over the past five years, yet its current checks suggest a more nuanced valuation picture where the Discounted Cash Flow (DCF) estimate points to meaningful upside while market multiples look closer to fair value. Over five years, Brown-Forman’s share price has fallen about 56.6%, which raises questions about whether expectations have reset too far compared to the company’s fundamentals. Future cash flow and margin expectations...

MasTec (MTZ) has drawn fresh investor attention after completing a US$647.764 million fixed income offering in 5.850% senior notes due 2036, a move that could influence its funding mix and project pipeline. See our latest analysis for MasTec. MasTec’s share price has been volatile around this funding move, with the stock down 7.39% on a 1-day share price return and 27.09% over 90 days, yet still showing a 23.05% year to date share price gain and a 59.84% 1-year total shareholder return. This...

Verizon Communications (NYSE: VZ) has had its petition rejected by the U.S. Supreme Court, leaving in place a multimillion dollar FCC fine tied to sales of customers' real time location data. The decision ends Verizon's legal challenge and confirms the financial penalty imposed over its handling of sensitive user information. The outcome renews focus on Verizon's regulatory exposure and the privacy rules that apply to major U.S. telecom carriers. With regulators tightening their focus on...

Chevron recently confirmed an oil and gas condensate discovery at the 105-4X exploration well in Angola’s offshore Block 0, which it is evaluating for development as a tie-back to nearby existing facilities to potentially accelerate development timelines and lower unit costs. This Angola find highlights Chevron’s focus on infrastructure-led exploration in Sub-Saharan Africa, adding to its resource base while aiming to use existing platforms and pipelines more efficiently. We’ll now examine...

Market discussion around TAL Education Group (NYSE:TAL) has picked up after commentators highlighted its lower PEG ratio and P/B ratio compared with peers. This has prompted investors to reassess the stock’s current pricing and earnings outlook. See our latest analysis for TAL Education Group. TAL Education Group's recent trading reflects this renewed interest, with a 1-month share price return of 17.48% and a 3-month share price return of 14.90% indicating building momentum. The 3-year total...

CBL & Associates Properties (CBL) is back in focus after its August earnings update, which showed higher quarterly and half year sales and net income, along with new full year 2026 earnings guidance. See our latest analysis for CBL & Associates Properties. At a share price of US$56.66, CBL & Associates Properties has cooled slightly in the very short term, yet a 30 day share price return of 2.51% and 90 day share price return of 18.73% sit alongside a year to date share price return of 53.43%...

In August 2026, Insmed Incorporated reported second-quarter 2026 results showing a net loss of US$13.24 million, down sharply from US$321.69 million a year earlier, with basic and diluted loss per share from continuing operations at US$0.06 versus US$1.70. Over the first half of 2026, Insmed’s net loss narrowed to US$176.81 million from a very large loss of US$578.27 million, suggesting meaningfully lower cash burn and tighter cost control compared with the prior year period. We’ll now...

In August 2026, The Allstate Corporation reported past second‑quarter 2026 results showing revenue of US$18,596 million and net income of US$3,271 million, alongside higher basic and diluted earnings per share from continuing operations than a year earlier. Allstate also completed a US$1,404.01 million share repurchase program that reduced its share count, a move that can amplify earnings per share and align with analysts’ positive assessment of its earnings outlook and valuation...

Universal (UVV) reported first quarter 2026 results with sales of US$523.78 million and a net loss of US$5.02 million, along with a quarterly dividend declaration and completion of a share repurchase tranche. See our latest analysis for Universal. At a share price of US$44.43, Universal has seen its 30 day share price return fall 16.39% and its year to date share price return decline 15.5%. However, the 3 year total shareholder return of 13.16% and 5 year total shareholder return of 22.98%...

Incyte stock has delivered a strong 90.6% return over the past three years, yet on broad valuation checks it no longer looks like an obvious bargain. Over the last three years, Incyte has returned 90.6%, which puts more pressure on today’s buyers to justify the current price with future execution. The key support for the current valuation can come from how reliably Incyte converts its pipeline and products into cash flow. Any disappointment in revenue growth or margins may weigh heavily...

Doximity stock has had a difficult five year run, with the share price down 71.8%. However, the current valuation checks suggest the picture today is more nuanced, as the Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful upside while the market based multiples look closer to fair. Over the past five years, Doximity has delivered a share price decline of 71.8%, which means anyone looking at the stock now is likely focused on whether that weakness has already been...